(1)要約四半期連結財政状態計算書
|
(単位:百万円)
|
|
|
|
前連結会計年度 (2025年3月31日)
|
|
当第3四半期連結会計期間 (2025年12月31日)
|
|
資産
|
|
|
|
|
|
流動資産
|
|
|
|
|
|
現金及び現金同等物
|
|
209,838
|
|
214,768
|
|
営業債権及びその他の債権
|
|
593,836
|
|
604,637
|
|
その他の金融資産
|
|
45,015
|
|
62,115
|
|
棚卸資産
|
|
625,243
|
|
661,400
|
|
その他の流動資産
|
|
49,993
|
|
57,872
|
|
小計
|
|
1,523,925
|
|
1,600,792
|
|
売却目的で保有する資産
|
|
59,209
|
|
-
|
|
流動資産合計
|
|
1,583,134
|
|
1,600,792
|
|
非流動資産
|
|
|
|
|
|
有形固定資産
|
|
759,266
|
|
773,384
|
|
のれん
|
|
257,811
|
|
270,092
|
|
無形資産
|
|
239,319
|
|
228,279
|
|
持分法で会計処理されている 投資
|
|
287,977
|
|
200,345
|
|
その他の金融資産
|
|
177,405
|
|
296,252
|
|
退職給付に係る資産
|
|
72,618
|
|
74,517
|
|
繰延税金資産
|
|
34,608
|
|
37,931
|
|
その他の非流動資産
|
|
27,646
|
|
28,834
|
|
非流動資産合計
|
|
1,856,650
|
|
1,909,634
|
|
資産合計
|
|
3,439,784
|
|
3,510,426
|
|
|
|
|
|
|
|
(単位:百万円)
|
|
|
|
前連結会計年度 (2025年3月31日)
|
|
当第3四半期連結会計期間 (2025年12月31日)
|
|
負債及び資本
|
|
|
|
|
|
負債
|
|
|
|
|
|
流動負債
|
|
|
|
|
|
社債及び借入金
|
|
252,892
|
|
256,022
|
|
営業債務及びその他の債務
|
|
488,132
|
|
473,589
|
|
その他の金融負債
|
|
81,364
|
|
60,535
|
|
未払法人所得税等
|
|
10,627
|
|
8,785
|
|
引当金
|
|
89,711
|
|
102,724
|
|
その他の流動負債
|
|
109,360
|
|
118,247
|
|
小計
|
|
1,032,086
|
|
1,019,902
|
|
売却目的で保有する資産に 直接関連する負債
|
|
6,661
|
|
-
|
|
流動負債合計
|
|
1,038,747
|
|
1,019,902
|
|
非流動負債
|
|
|
|
|
|
社債及び借入金
|
|
1,033,236
|
|
965,463
|
|
その他の金融負債
|
|
91,157
|
|
88,566
|
|
退職給付に係る負債
|
|
24,841
|
|
23,781
|
|
引当金
|
|
25,974
|
|
26,033
|
|
繰延税金負債
|
|
111,048
|
|
93,170
|
|
その他の非流動負債
|
|
40,366
|
|
27,358
|
|
非流動負債合計
|
|
1,326,622
|
|
1,224,371
|
|
負債合計
|
|
2,365,369
|
|
2,244,273
|
|
資本
|
|
|
|
|
|
資本金
|
|
90,059
|
|
90,179
|
|
資本剰余金
|
|
-
|
|
117
|
|
利益剰余金
|
|
640,611
|
|
697,783
|
|
自己株式
|
|
△8,361
|
|
△8,364
|
|
その他の資本の構成要素
|
|
174,871
|
|
250,203
|
|
売却目的で保有する資産に関連する その他の包括利益
|
|
3,610
|
|
-
|
|
親会社の所有者に帰属する持分 合計
|
|
900,790
|
|
1,029,918
|
|
非支配持分
|
|
173,625
|
|
236,235
|
|
資本合計
|
|
1,074,415
|
|
1,266,153
|
|
負債及び資本合計
|
|
3,439,784
|
|
3,510,426
|
|
|
|
|
|
|
E00752
40050
住友化学株式会社
SUMITOMO CHEMICAL COMPANY, LIMITED
四半期第3号参考様式 [IFRS](連結)
IFRS
true
cte
2025-04-01
2025-12-31
Q3
2026-03-31
2024-04-01
2024-12-31
2025-03-31
1
false
false
false
40050
2026-02-03
40050
2025-12-31
40050
2025-12-31
jpigp_cor:CapitalSurplusIFRSMember
40050
2025-12-31
jpigp_cor:EffectivePortionOfCashFlowHedgesIFRSMember
40050
2025-12-31
jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember
40050
2025-12-31
jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember
40050
2025-12-31
jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember
40050
2025-12-31
jpigp_cor:NonControllingInterestsIFRSMember
40050
2025-12-31
jpigp_cor:OtherComponentsOfEquityIFRSMember
40050
2025-12-31
jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember
40050
2025-12-31
jpigp_cor:RetainedEarningsIFRSMember
40050
2025-12-31
jpigp_cor:ShareCapitalIFRSMember
40050
2025-12-31
jpigp_cor:TreasurySharesIFRSMember
40050
2025-12-31
tse-qcediffr-40050:OtherComprehensiveIncomeRelatedToAssetsHeldForSaleIFRSMember
40050
2025-04-01
2025-12-31
40050
2025-04-01
2025-12-31
jpigp_cor:CapitalSurplusIFRSMember
40050
2025-04-01
2025-12-31
jpigp_cor:EffectivePortionOfCashFlowHedgesIFRSMember
40050
2025-04-01
2025-12-31
jpcrp_cor:EntityTotalMember
40050
2025-04-01
2025-12-31
jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember
40050
2025-04-01
2025-12-31
jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember
40050
2025-04-01
2025-12-31
jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember
40050
2025-04-01
2025-12-31
jpigp_cor:NonControllingInterestsIFRSMember
40050
2025-04-01
2025-12-31
jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember
40050
2025-04-01
2025-12-31
jpigp_cor:OtherComponentsOfEquityIFRSMember
40050
2025-04-01
2025-12-31
jpcrp_cor:ReconcilingItemsMember
40050
2025-04-01
2025-12-31
jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember
40050
2025-04-01
2025-12-31
jpcrp_cor:ReportableSegmentsMember
40050
2025-04-01
2025-12-31
jpigp_cor:RetainedEarningsIFRSMember
40050
2025-04-01
2025-12-31
jpigp_cor:ShareCapitalIFRSMember
40050
2025-04-01
2025-12-31
jpigp_cor:TreasurySharesIFRSMember
40050
2025-04-01
2025-12-31
tse-qcediffr-40050:AdvancedMedicalSolutionsReportableSegmentMember
40050
2025-04-01
2025-12-31
tse-qcediffr-40050:AgroAndLifeSolutionsReportableSegmentMember
40050
2025-04-01
2025-12-31
tse-qcediffr-40050:EssentialAndGreenMaterialsReportableSegmentMember
40050
2025-04-01
2025-12-31
tse-qcediffr-40050:ICTAndMobilitySolutionsReportableSegmentMember
40050
2025-04-01
2025-12-31
tse-qcediffr-40050:OtherComprehensiveIncomeRelatedToAssetsHeldForSaleIFRSMember
40050
2025-04-01
2025-12-31
tse-qcediffr-40050:SumitomoPharmaReportableSegmentMember
40050
2024-12-31
40050
2024-12-31
jpigp_cor:CapitalSurplusIFRSMember
40050
2024-12-31
jpigp_cor:EffectivePortionOfCashFlowHedgesIFRSMember
40050
2024-12-31
jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember
40050
2024-12-31
jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember
40050
2024-12-31
jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember
40050
2024-12-31
jpigp_cor:NonControllingInterestsIFRSMember
40050
2024-12-31
jpigp_cor:OtherComponentsOfEquityIFRSMember
40050
2024-12-31
jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember
40050
2024-12-31
jpigp_cor:RetainedEarningsIFRSMember
40050
2024-12-31
jpigp_cor:ShareCapitalIFRSMember
40050
2024-12-31
jpigp_cor:TreasurySharesIFRSMember
40050
2024-12-31
tse-qcediffr-40050:OtherComprehensiveIncomeRelatedToAssetsHeldForSaleIFRSMember
40050
2025-03-31
40050
2025-03-31
jpigp_cor:CapitalSurplusIFRSMember
40050
2025-03-31
jpigp_cor:EffectivePortionOfCashFlowHedgesIFRSMember
40050
2025-03-31
jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember
40050
2025-03-31
jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember
40050
2025-03-31
jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember
40050
2025-03-31
jpigp_cor:NonControllingInterestsIFRSMember
40050
2025-03-31
jpigp_cor:OtherComponentsOfEquityIFRSMember
40050
2025-03-31
jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember
40050
2025-03-31
jpigp_cor:RetainedEarningsIFRSMember
40050
2025-03-31
jpigp_cor:ShareCapitalIFRSMember
40050
2025-03-31
jpigp_cor:TreasurySharesIFRSMember
40050
2025-03-31
tse-qcediffr-40050:OtherComprehensiveIncomeRelatedToAssetsHeldForSaleIFRSMember
40050
2024-04-01
2024-12-31
40050
2024-04-01
2024-12-31
jpigp_cor:CapitalSurplusIFRSMember
40050
2024-04-01
2024-12-31
jpigp_cor:EffectivePortionOfCashFlowHedgesIFRSMember
40050
2024-04-01
2024-12-31
jpcrp_cor:EntityTotalMember
40050
2024-04-01
2024-12-31
jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember
40050
2024-04-01
2024-12-31
jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember
40050
2024-04-01
2024-12-31
jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember
40050
2024-04-01
2024-12-31
jpigp_cor:NonControllingInterestsIFRSMember
40050
2024-04-01
2024-12-31
jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember
40050
2024-04-01
2024-12-31
jpigp_cor:OtherComponentsOfEquityIFRSMember
40050
2024-04-01
2024-12-31
jpcrp_cor:ReconcilingItemsMember
40050
2024-04-01
2024-12-31
jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember
40050
2024-04-01
2024-12-31
jpcrp_cor:ReportableSegmentsMember
40050
2024-04-01
2024-12-31
jpigp_cor:RetainedEarningsIFRSMember
40050
2024-04-01
2024-12-31
jpigp_cor:ShareCapitalIFRSMember
40050
2024-04-01
2024-12-31
jpigp_cor:TreasurySharesIFRSMember
40050
2024-04-01
2024-12-31
tse-qcediffr-40050:AdvancedMedicalSolutionsReportableSegmentMember
40050
2024-04-01
2024-12-31
tse-qcediffr-40050:AgroAndLifeSolutionsReportableSegmentMember
40050
2024-04-01
2024-12-31
tse-qcediffr-40050:EssentialAndGreenMaterialsReportableSegmentMember
40050
2024-04-01
2024-12-31
tse-qcediffr-40050:ICTAndMobilitySolutionsReportableSegmentMember
40050
2024-04-01
2024-12-31
tse-qcediffr-40050:OtherComprehensiveIncomeRelatedToAssetsHeldForSaleIFRSMember
40050
2024-04-01
2024-12-31
tse-qcediffr-40050:SumitomoPharmaReportableSegmentMember
40050
2024-03-31
40050
2024-03-31
jpigp_cor:CapitalSurplusIFRSMember
40050
2024-03-31
jpigp_cor:EffectivePortionOfCashFlowHedgesIFRSMember
40050
2024-03-31
jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember
40050
2024-03-31
jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember
40050
2024-03-31
jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember
40050
2024-03-31
jpigp_cor:NonControllingInterestsIFRSMember
40050
2024-03-31
jpigp_cor:OtherComponentsOfEquityIFRSMember
40050
2024-03-31
jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember
40050
2024-03-31
jpigp_cor:RetainedEarningsIFRSMember
40050
2024-03-31
jpigp_cor:ShareCapitalIFRSMember
40050
2024-03-31
jpigp_cor:TreasurySharesIFRSMember
40050
2024-03-31
tse-qcediffr-40050:OtherComprehensiveIncomeRelatedToAssetsHeldForSaleIFRSMember
iso4217:JPY
iso4217:JPY
xbrli:shares
xbrli:pure